Clinical trials: Papulopustular Rosacea
Papulopustular Rosacea
A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular…
- Trial name
- NCT07681271
- Testing
- LOU064
- Where
- 12 sites in United States, Bulgaria and 6 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Epidermal Growth Factor, Papulopustular Rosacea
Study to Evaluate the Safety of ATR-04
This is a multicenter, randomized, double-blind, placebo-controlled phase 1b/2a study designed to evaluate the safety of an investigational product called ATR-04, to reduce the severity of epidermal growth factor receptor…
- Trial name
- NCT04731259
- Testing
- ATR-04
- Sponsor
- Azitra Inc.
Papulopustular Rosacea
A Safety and Efficacy Study to Evaluate Rosacea
To evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with rosacea.
- Trial name
- NCT03883945
- Testing
- AIV001, Vehicle
- Where
- United States
- Sponsor
- AiViva BioPharma, Inc.
Rosacea, Papulopustular
Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device
10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device
- Trial name
- NCT05592548
- Testing
- cold atmospheric plasma
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Skin Center Dermatology Group
Papulopustular Rosacea
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-1 (NCT05296629)
- Testing
- DFD-29, Doxycycline
- Where
- 27 sites in United States
- Volunteers
- 323 people
- Sponsor
- Journey Medical Corporation
Papulopustular Rosacea
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are…
- Trial name
- MVOR-2 (NCT05343455)
- Testing
- DFD-29, Doxycycline
- Where
- 24 sites in United States, Germany
- Volunteers
- 330 people
- Sponsor
- Journey Medical Corporation
Papulopustular Rosacea
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes.
- Trial name
- NCT05150587
- Testing
- Rifaximin
- Where
- 38 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alfasigma S.p.A.
Papulopustular Rosacea
Study of TP-04 in Participants With Papulopustular Rosacea
This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).
- Trial name
- NCT05838170
- Testing
- Lotilaner Gel, 2.0%, Vehicle control gel
- Where
- 5 sites in Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Papulopustular Rosacea
A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily
To assess the efficacy and tolerability of azelaic acid 15% gel applied once daily versus twice daily in the treatment of patients with papulopustular rosacea.
- Trial name
- NCT00417937
- Testing
- azelaic acid 15% gel
- Where
- Germany
- Volunteers
- 98 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel. Assessment of safety after repeated skin application.
- Trial name
- NCT01257919
- Testing
- Azelaic Acid Foam, Azelaic Acid Gel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
- Trial name
- NCT01555463
- Testing
- Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
- Where
- 49 sites in United States
- Volunteers
- 961 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
The overall objective of this study is to assess how the use of the drug may shift the skin microbiome and skin biophysical properties.
- Trial name
- NCT05675501
- Testing
- Encapsulated Benzoyl Peroxide Cream
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
- Trial name
- NCT02268474
- Testing
- 532nm KTP Laser vs 595nm Pulse Dye Laser
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
- Trial name
- NCT01872715
- Testing
- Oracea
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea
The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.
- Trial name
- NCT03276936
- Testing
- FMX103 1.5%
- Where
- 79 sites in United States
- Volunteers
- 504 people
- Sponsor
- Vyne Therapeutics Inc.
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03564119
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).
- Trial name
- NCT03564145
- Testing
- S5G4T-1
- Where
- United States
- Volunteers
- 547 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea
A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
- Trial name
- NCT03448939
- Testing
- S5G4T-1, S5G4T-2
- Where
- United States
- Volunteers
- 361 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01494467
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 688 people
- Sponsor
- Galderma R&D